Patrick W Mellors
Overview
Explore the profile of Patrick W Mellors including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
37
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bhagwat A, Torres L, Shestova O, Shestov M, Mellors P, Fisher H, et al.
Nat Med
. 2024 Sep;
30(12):3697-3708.
PMID: 39333315
Acute myeloid leukemia (AML) is a rapidly progressive malignancy without effective therapies for refractory disease. So far, chimeric antigen receptor (CAR) T cell therapy in AML has not recapitulated the...
2.
Mellors P, Kourelis T, Go R, Muchtar E, Gertz M, Kumar S, et al.
Am J Hematol
. 2021 Nov;
97(2):209-215.
PMID: 34822175
Thromboses are prevalent in POEMS syndrome, but few risk factors for POEMS-associated thrombosis have been identified. The objective of this study is to identify novel risk factors for POEMS-associated thrombosis....
3.
Mellors P, Kohlhagen M, Dasari S, Willrich M, Gertz M, Kumar S, et al.
Clin Chem Lab Med
. 2021 Jun;
59(11):e430-e433.
PMID: 34114387
No abstract available.
4.
Mellors P, Dasari S, Kohlhagen M, Kourelis T, Go R, Muchtar E, et al.
Blood Cancer J
. 2021 Jun;
11(6):110.
PMID: 34099625
No abstract available.
5.
Mellors P, Dasari S, Kohlhagen M, Kourelis T, Go R, Muchtar E, et al.
Blood Cancer J
. 2021 Mar;
11(3):50.
PMID: 33664227
Immunoenrichment-based matrix assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOF-MS), termed MASS-FIX, offers several advantages over immunofixation for the detection and isotyping of serum monoclonal protein, including superior sensitivity and...
6.
Mellors P, Binder M, Ketterling R, Greipp P, Baughn L, Peterson J, et al.
Blood Adv
. 2020 May;
4(10):2236-2244.
PMID: 32442300
Metaphase cytogenetic abnormalities, plasma cell proliferation index (PCPro), and gain 1q by fluorescence in situ hybridization (FISH) are associated with inferior survival in newly diagnosed multiple myeloma (MM) treated with...
7.
Mellors P, Binder M, Buadi F, Lacy M, Gertz M, Dispenzieri A, et al.
Leuk Lymphoma
. 2019 May;
60(12):2960-2967.
PMID: 31096812
The prognostic significance of novel agent-induced thrombocytopenia in newly diagnosed multiple myeloma (MM) is unknown. We identified 665 newly diagnosed patients receiving proteasome inhibitors and/or immunomodulators with pretreatment platelet counts...
8.
Mellors P, Binder M, Buadi F, Lacy M, Gertz M, Dispenzieri A, et al.
Am J Hematol
. 2018 Apr;
93(7):889-894.
PMID: 29659048
Response rates in newly diagnosed multiple myeloma have improved dramatically with the introduction of highly effective novel therapies. However, survival in patients achieving optimal responses to initial treatment can vary...